^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners

TEST:
VENTANA MSLN (SP74) ASSAY

Company:
Roche
Type:
Laboratory Developed Test
Related tests:
Evidence

News

1m
Exploring the potential role of four Rhizophagus irregularis nuclear effectors: opportunities and technical limitations. (PubMed, Front Plant Sci)
lycopersicum and demonstrated by transcriptomics the effectors possible involvement in different molecular processes, i.e., the regulation of DNA replication, methylglyoxal detoxification, and RNA splicing. We conclude that R. irregularis nuclear-localized effector proteins may act on different pathways to modulate symbiosis and plant physiology and discuss the pros and cons of the tools used.
Journal
|
VENTANA MSLN (SP74) ASSAY
4ms
Binding interactions and in silico ADME prediction of isoconessimine derivatives as potent acetylcholinesterase inhibitors. (PubMed, J Mol Graph Model)
The SwissADME investigation suggested that four compounds (7a, 7c, 7d and 7f) agree with the rules of drug-likeness. The steric and electronic effects on the aryloxy-substitutional ethyl group as important factors in the AChE inhibition were also discussed, which brings a better understanding of Alzheimer's disease drug development.
Journal
|
NAPSA (Napsin A Aspartic Peptidase)
|
VENTANA MSLN (SP74) ASSAY
5ms
Clinical Significance Of Mesothelin Expression And Its Correlation With HER2 In Gynecologic Carcinosarcoma (ESGO 2024)
In this study, MSLN expression is widely observed in UCS. Moreover, high-MSLN expression is a favorable prognostic factor for UCS, which could be a promising therapeutic target, regardless of HER2 expression. This study was published in the Journal of Gynecologic Oncology.
Clinical
|
HER-2 (Human epidermal growth factor receptor 2) • MSLN (Mesothelin)
|
HER-2 negative • HER-2 expression • MSLN expression • MSLN positive
|
VENTANA MSLN (SP74) ASSAY
8ms
Mesothelin expression in gynecologic carcinosarcoma: clinicopathological significance and correlation with HER2 expression. (PubMed, J Gynecol Oncol)
MSLN expression is widely observed in gynecological carcinosarcomas. Moreover, high-MSLN expression is a favorable prognostic factor for UCS. MSLN could be a promising therapeutic target for UCS, even in the era of anti-HER2 therapy.
Journal
|
HER-2 (Human epidermal growth factor receptor 2) • MSLN (Mesothelin)
|
HER-2 negative • HER-2 expression • MSLN expression • MSLN positive
|
VENTANA MSLN (SP74) ASSAY
over1year
High mesothelin expression is correlated with non-squamous cell histology and poor survival in cervical cancer: a retrospective study. (PubMed, BMC Cancer)
MSLN was highly expressed in patients with cervical cancer, especially in those with non-SCC. High MSLN expression in the primary lesion was significantly associated with poor OS, and its expression was maintained in metastatic lesions. Our findings indicate that MSLN may be an attractive therapeutic target for cervical cancer.
Retrospective data • Journal
|
MSLN (Mesothelin)
|
MSLN expression • MSLN positive
|
VENTANA MSLN (SP74) ASSAY
over3years
[VIRTUAL] Mesothelin expression varies by histological type in patients with cervical cancer and is reduced in metastatic tumors (AACR 2021)
MSLN was highly expressed in cervical adenocarcinoma, including adenosquamous carcinoma and adenocarcinoma, gastric type. Despite the MSLN-high in the primary tumor, MSLN expression was reduced in metastatic tumors in 37.5% of patients. The MSLN may be a potential target for cervical adenocarcinoma, and reassessment of MSLN expression at metastatic sites is desirable to maximize the therapeutic effects.
Clinical
|
MSLN (Mesothelin)
|
MSLN expression • MSLN positive
|
VENTANA MSLN (SP74) ASSAY